Top-line growth from products you already make. On plant you already run.
No new chemistry, no new plant, no new regulatory file — and no capex conversation gating it. That is what adjacent-market development is worth when it stops being a project somebody has to champion and becomes a workflow that runs.
What actually moves, and where it shows up.
Six things change. None of them requires new chemistry, a new plant or a new regulatory file.
| Today | What moves on the P&L | |
|---|---|---|
| Adjacent selling runs as a project, then stops. | › | Adjacent selling runs as a process. |
| Molecules stay in their lane. | › | Top-line growth from products you already make. |
| Plant runs under capacity. | › | Improved ROCE from plant you already run. |
| Growth waits for capex. | › | Growth with no new capital. |
| Same markets, same buyers. | › | New customers in those markets — the ones not basic in your molecule. |
| Knowledge leaves with people. | › | Knowledge that compounds. |
Every one of those is a second-order effect of a first-order fact: your molecule already does something an industry you do not serve is paying somebody else for. The rest of this page is about why that is hard to act on, and what changes when it is not.
Building adjacent sales growth is the hard part.
Not the reading — the reading is only where it starts. Turning a molecule into revenue in an industry you have never sold to has to get past three separate walls, and only one of them is about budget.
Finding it
Public, but scattered. And most of it is hard to read on purpose. Dossiers written by lawyers for regulators. Patents that disclose as little as the law allows. Papers written for specialists in another field. The line that decides it sits in a clause.
Proving it is worth selling
That needs someone who reads a patent and knows what the molecule really does, and knows which application is worth a call, and can build the case management will back. Most companies have one or two such people. They are already committed.
Doing it again next quarter
Done properly the work is a team assembled across functions and held together for months. That is affordable once. So adjacent growth gets done properly once — and then not again.
And no, search does not solve it.
Why not a search engine? It ranks popularity, not evidence
Search returns what is linked to, not what is load-bearing. The document that decides whether your molecule can serve an application is often cited by nobody, written for a different discipline, and sitting on page nine.
Why not a general AI? It answers from memory, not from the record
A general model answers from training: the internet as it was, summarised. Not a reading of the record. You get a fluent answer with no source to check, and no account of what it missed.
Why not your own files? The inside view is stale, and already explored
The material inside the company is dated, and the same ground has been gone over again and again. The places that are genuinely new are, by definition, the ones nobody in the building has looked at.
A workflow, not a search.
A search answers a question once and leaves the business unchanged. A workflow runs on a cadence and is fitted to your company: your vocabulary, what you already sell, and your own sources, wired in beside the public record.
An engine fitted to your company makes the reading cheap enough to repeat, and it keeps what was learned, so the second chemistry is easier than the first. It decides nothing. A person still signs.
Two engagements, and the new market applications they found.
candidate markets found for one established chemical — 39 already served, and subtracted before ranking
candidate markets for a fermentation-derived biosurfactant, and three questions no source publishes at all
from starting to a sourced go-to-market foundation on that first engagement, with the gaps named
Start with one chemistry. Let the result decide the rest.
A low-cost test on one product, worked end to end and judged on what comes back. Every lead shows its source, so you can judge it yourself in the first meeting. A cheap “nothing here” is a legitimate answer.
571-276-9104 · Okatie, South Carolina
LinkedIn: jimpuckace